NDATOPICALLOTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DUOBRII (halobetasol propionate and tazarotene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2019.
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOBRII is a topical lotion combining halobetasol propionate (potent corticosteroid) and tazarotene (retinoid) for treatment of plaque psoriasis. The dual mechanism targets both inflammation and abnormal keratinocyte differentiation via retinoid receptor activation. It represents a fixed-dose combination approach to enhance efficacy in moderate-to-severe psoriasis.
$0.927MPart D
Peak9.8 years to LOEProduct is at peak commercial maturity with modest Part D penetration (~863 claims in 2023), suggesting a niche positioning within the topical retinoid psoriasis market with limited team expansion opportunities.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Started Oct 2022
15 enrolled
Acne Keloidalis NuchaeAKN
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
DUOBRII roles are concentrated in commercial and market access functions given its niche position and modest Part D uptake (~863 claims). The lack of linked job openings suggests limited hiring; career advancement would require lateral moves to high-growth Bausch + Lomb franchises (e.g., CABTREO) or advocacy for market-share defense in competitive dermatology.
Worked on DUOBRII at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.